Evidence map›Paper›PMID 36371767›Full record

ArticleInternal medicine journal2023

Australia and New Zealand Transplant and Cellular Therapies (ANZTCT) position statement: COVID-19 management in patients with haemopoietic stem cell transplant and chimeric antigen receptor T cell.

Jacinta Perram, Duncan Purtill, Ashish Bajel, Jason Butler, Tracey O'Brien, Benjamin Teh, Nicole Gilroy, Phoebe J Ho, Richard Doocey, Thomas Hills and 24 more

Abstract readConsensus Statement
PubMed Full text at PMC Publisher
In one paragraph

Article in Internal medicine journal, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

34 authors.

Jacinta PerramHaematology Department, Westmead Hospital, Sydney, New South Wales, Australia.ORCID 0000-0003-0054-7906
Duncan PurtillHaematology department, Fiona Stanley Hospital, Western Australia, Perth, Australia.
Ashish BajelClinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Jason ButlerHaematology department, Royal Brisbane and Women's Hospital, Queensland, Brisbane, Australia.
Tracey O'BrienHaematology department, Sydney Children's Hospital, New South Wales, Sydney, Australia.
Benjamin TehHaematology department, National Centre for Infections in Cancer and Department of Infectious Diseases, Peter MacCallum Cancer Institute, Victoria, Melbourne, Australia.ORCID 0000-0003-0213-5470
Nicole GilroyHaematology department, Centre for Infectious Diseases and Microbiology, Westmead Hospital, New South Wales, Sydney, Australia.
Phoebe J HoHaematology department, Royal Prince Alfred Hospital and the University of Sydney, New South Wales, Sydney, Australia.
Richard DooceyHaematology department, Auckland City Hospital, Auckland, New Zealand.
Thomas HillsHaematology department, Auckland City Hospital, Auckland, New Zealand.
Travis PereraHaematology department, Wellington Blood and Cancer Centre, Wellington, New Zealand.
Genevieve DouglasHaematology department, Austin Hospital, Victoria, Melbourne, Australia.
Shanti RamachandranDepartment of Clinical Haematology, Oncology, Blood and Marrow Transplantation, Perth Children's Hospital, Perth, Western Australia, Australia.
Lynette CheeClinical Haematology, Peter MacCallum Cancer Centre and The Royal Melbourne Hospital, Melbourne, Victoria, Australia.
Judith TrotmanHaematology department, Concord Repatriation General Hospital and University of Sydney, New South Wales, Sydney, Australia.ORCID 0000-0001-8009-4593
Robert WeinkoveHaematology department, Wellington Blood and Cancer Centre and Cancer Immunotherapy Programme, Malaghan Institute of Medical Research, Wellington, New Zealand.
Steven KeoghHaematology department, University of Sydney and Westmead Hospital, New South Wales, Sydney, Australia.
Chris FraserHaematology department, Children's Health Queensland Hospital and Health Service, Queensland, Brisbane, Australia.
Tara CochraneHaematology department, Gold Coast University Hospital, Queensland, Gold Coast, Australia.ORCID 0000-0002-2668-1399
Anne-Marie WatsonHaematology department, Liverpool Hospital, New South Wales, Sydney, Australia.
Peter DiamondLeukaemia Foundation, Sydney, New South Wales, Australia.
Maya LatimerHaematology department, Canberra Hospital, Australian Capital Territory, Canberra, Australia.
Ian IrvingICON Cancer Centre, Brisbane, Queensland, Australia.
Emily BlythHaematology department, University of Sydney and Westmead Hospital, New South Wales, Sydney, Australia.
Chan CheahHaematology department, Sir Charles Gairdner Hospital, Western Australia, Perth, Australia.
Theresa ColeHaematology department, The Royal Children's Hospital Melbourne, Victoria, Melbourne, Australia.
Sam MillikenHaematology department, St Vincent's Hospital Sydney and School of Clinical Medicine, Faculty of Medicine and Health, UNSW, New South Wales, Sydney, Australia.
Hung YangAustralian Bone Marrow Donor Registry, Sydney, New South Wales, Australia.
Matthew GreenwoodHaematology department, Royal North Shore Hospital, New South Wales, Sydney, Australia.ORCID 0000-0002-3667-2613
Peter BardyHaematology department, Royal Adelaide Hospital, South Australia, Adelaide, Australia.
Glen KennedyHaematology department, Royal Brisbane and Women's Hospital, Queensland, Brisbane, Australia.
Stephen LarsenHaematology department, Royal Prince Alfred Hospital and the University of Sydney, New South Wales, Sydney, Australia.
Rachel ConyersHaematology department, The Royal Children's Hospital Melbourne, Victoria, Melbourne, Australia.
Nada HamadHaematology department, St Vincent's Hospital Sydney and School of Clinical Medicine, Faculty of Medicine and Health, UNSW, New South Wales, Sydney, Australia.ORCID 0000-0001-7929-1450

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Patients with post-haemopoietic stem cell transplant or chimeric antigen receptor T -cell (CAR-T) therapy face a significant risk of morbidity and mortality from coronavirus disease 2019 because of their immunosuppressed state. As case numbers in Australia and New Zealand continue to rise, guidance on management in this high-risk population is needed. Whilst we have learned much from international colleagues who faced high infection rates early in the pandemic, guidance relevant to local health system structures, medication availability and emerging therapies is essential to equip physicians to manage our patients optimally.

Indexed as

COVID-19Hematopoietic Stem Cell TransplantationReceptors, Chimeric AntigenHumansNew ZealandT-LymphocytesReceptors, Chimeric Antigenallogeneic stem cell transplantautologous stem cell transplantCAR-T cellCOVID-19

Identifiers

PMID36371767
PMCPMC9878098

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.